ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
The group is keeping faith with the novel target KLK2.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
Abstract titles reveal some of ASCO’s key datasets.